EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SK Bioscience Co's Enterprise Value is ₩3,164,028 Mil.
SK Bioscience Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-20,949 Mil. Therefore, SK Bioscience Co's EV-to-FCF for today is -151.03.
The historical rank and industry rank for SK Bioscience Co's EV-to-FCF or its related term are showing as below:
XKRX:302440'
s EV-to-FCF Range Over the Past 10 Years
Min: -192.71 Med: 26.58 Max: 94.82
Current: -150.67
During the past 6 years, the highest EV-to-FCF of SK Bioscience Co was 94.82. The lowest was -192.71. And the median was 26.58.
XKRX:302440's EV-to-FCF is ranked worse than 100% of 393
companies
in the Biotechnology industry
Industry Median: 4.27
vs XKRX:302440: -150.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for SK Bioscience Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SK Bioscience Co's EV-to-FCF
For the Biotechnology subindustry, SK Bioscience Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SK Bioscience Co's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SK Bioscience Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where SK Bioscience Co's EV-to-FCF falls into.
SK Bioscience Co's current Enterprise Value is ₩3,164,028 Mil.
SK Bioscience Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-20,949 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SK Bioscience Co (XKRX:302440) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
SK Bioscience Co's PE Ratio for today is calculated as:
SK Bioscience Co's share price for today is ₩57500.00.
SK Bioscience Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩288.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SK Bioscience Co EV-to-FCF Related Terms
Thank you for viewing the detailed overview of SK Bioscience Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
SK Bioscience Co (XKRX:302440) Business Description
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:302440 has been successfully added to your 